Cubist Systematic Strategies LLC Invests $774,000 in Phreesia, Inc. $PHR

Key Points

• Cubist Systematic Strategies LLC has acquired 30,265 shares of Phreesia, Inc. valued at approximately $774,000, indicating growing institutional interest in the company.
• Key analysts have upgraded Phreesia's stock ratings, with price targets revised upwards, including a raise from $28.00 to $35.00 by KeyCorp.
• Phreesia reported a Q2 earnings per share (EPS) of $0.01, exceeding analyst estimates, along with a 14.9% revenue increase year-over-year.

Cubist Systematic Strategies LLC acquired a new position in shares of Phreesia, Inc. (NYSE:PHR - Free Report) in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 30,265 shares of the company's stock, valued at approximately $774,000. Cubist Systematic Strategies LLC owned approximately 0.05% of Phreesia as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in PHR. KBC Group NV acquired a new position in Phreesia in the 1st quarter valued at $74,000. CWM LLC raised its stake in Phreesia by 994.9% during the 1st quarter. CWM LLC now owns 4,040 shares of the company's stock worth $103,000 after buying an additional 3,671 shares during the period. Smartleaf Asset Management LLC raised its stake in shares of Phreesia by 53.0% in the first quarter. Smartleaf Asset Management LLC now owns 5,267 shares of the company's stock worth $137,000 after purchasing an additional 1,825 shares during the last quarter. GAMMA Investing LLC increased its position in shares of Phreesia by 10,605.7% during the first quarter. GAMMA Investing LLC now owns 5,674 shares of the company's stock valued at $145,000 after acquiring an additional 5,621 shares during the last quarter. Finally, BNP Paribas Financial Markets bought a new position in Phreesia during the fourth quarter valued at $163,000. 92.10% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

PHR has been the subject of a number of analyst reports. Wall Street Zen raised Phreesia from a "hold" rating to a "buy" rating in a report on Sunday, June 1st. KeyCorp raised their price target on Phreesia from $28.00 to $35.00 and gave the company an "overweight" rating in a research report on Monday, July 14th. Citigroup reiterated an "outperform" rating on shares of Phreesia in a report on Monday, September 8th. Truist Financial raised their target price on Phreesia from $35.00 to $36.00 and gave the stock a "buy" rating in a research note on Friday, September 5th. Finally, JMP Securities increased their target price on Phreesia from $30.00 to $34.00 and gave the stock a "market outperform" rating in a research report on Monday, September 8th. One research analyst has rated the stock with a Strong Buy rating and twelve have given a Buy rating to the company's stock. According to MarketBeat, Phreesia presently has an average rating of "Buy" and an average target price of $34.08.

Phreesia Stock Down 3.3%

PHR stock traded down $0.81 during trading on Monday, hitting $23.38. 1,692,430 shares of the company's stock traded hands, compared to its average volume of 1,110,740. The business has a fifty day simple moving average of $27.92 and a two-hundred day simple moving average of $26.44. The company has a quick ratio of 2.12, a current ratio of 2.12 and a debt-to-equity ratio of 0.02. Phreesia, Inc. has a 1 year low of $17.07 and a 1 year high of $32.76. The firm has a market capitalization of $1.40 billion, a P/E ratio of -55.67 and a beta of 0.72.

Phreesia (NYSE:PHR - Get Free Report) last posted its earnings results on Thursday, September 4th. The company reported $0.01 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.07) by $0.08. Phreesia had a negative net margin of 5.35% and a negative return on equity of 8.75%. The company had revenue of $117.26 million during the quarter, compared to the consensus estimate of $116.39 million. During the same period in the previous year, the firm posted ($0.03) earnings per share. The firm's quarterly revenue was up 14.9% on a year-over-year basis. Phreesia has set its FY 2026 guidance at EPS. Sell-side analysts anticipate that Phreesia, Inc. will post -1.1 EPS for the current year.

Insider Transactions at Phreesia

In other Phreesia news, Director Lisa Egbuonu-Davis sold 2,802 shares of the firm's stock in a transaction on Thursday, June 26th. The shares were sold at an average price of $27.67, for a total transaction of $77,531.34. Following the transaction, the director directly owned 22,037 shares of the company's stock, valued at approximately $609,763.79. This trade represents a 11.28% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP David Linetsky sold 23,729 shares of the firm's stock in a transaction dated Friday, June 27th. The shares were sold at an average price of $28.50, for a total transaction of $676,276.50. Following the completion of the sale, the senior vice president owned 193,510 shares of the company's stock, valued at $5,515,035. This trade represents a 10.92% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 109,292 shares of company stock worth $3,295,323. Insiders own 5.50% of the company's stock.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.